Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and cardiometabolic diseases, leveraging AI and extensive human datasets.
The collaboration, which initially focused on cardiovascular disease, now includes 20 drug programmes and could yield Valo Health up to $4.6bn in milestone payments.
Go deeper with GlobalData
Novo Nordisk executive vice-president and chief scientific officer Marcus Schindler stated: “We are very pleased with the progress we have made together with Valo during the first year of our collaboration, and we are excited to expand the scope to put a stronger focus on obesity and type 2 diabetes in addition to cardiovascular disease.
“We have already begun to realise the potential of combining the capabilities of Valo and Novo Nordisk to advance multiple AI-powered, human-centric programmes, and we believe this partnership will help Novo Nordisk fulfil our ambition to expand the number of new drug programmes we bring to the clinic.”
Valo Health will receive equity investment, an upfront payment and a potential milestone payment, totalling $190m.
The collaboration now encompasses additional drug programmes, with the potential for Valo Health to obtain milestone payments for up to 20 programmes, an increase from the initial 11.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe agreement also involves research and development funding and potential royalty payments.
The partnership will continue to leverage Valo Health’s Opal computational platform’s capabilities and combine these with Novo Nordisk’s expertise in cardiometabolic diseases.
The synergy has already led to the identification of multiple new targets that may lead to differentiated drug programmes.
Novo Nordisk and Valo Health will work to extract insights from human genetic and longitudinal patient data, focusing on the intersection of type 2 diabetes, obesity and cardiovascular disease.
Before this development, Variant Bio partnered with Novo Nordisk to focus on the identification of new targets to treat metabolic conditions.
